Science behind phase I clinical trials: targeting tumour cell development pathwa...
Dr Gary K. Schwartz - Memorial Sloan-Kettering Cancer Center, New York, USA
Science behind phase I clinical trials: targeting tumour cell development pathways ( Dr Gary K. Schwartz - Memorial Sloan-Kettering Cancer Center, New York, USA )
6 Jun 2013
Sorafenib stalls growth of treatment-resistant differentiated thyroid cancer
Dr Marcia Brose - University of Pennsylvania, Philadelphia, USA
Sorafenib stalls growth of treatment-resistant differentiated thyroid cancer ( Dr Marcia Brose - University of Pennsylvania, Philadelphia, USA )
2 Jun 2013
Sorafenib stalls growth of treatment-resistant differentiated thyroid cancer
Dr Marcia Brose - Abramson Cancer Center, University of Pennsylvania, USA
Sorafenib stalls growth of treatment-resistant differentiated thyroid cancer ( Dr Marcia Brose - Abramson Cancer Center, University of Pennsylvania, USA )
2 Jun 2013
New MEK inhibitor selumetinib is the first effective drug for advanced melanoma ...
Dr Richard D. Carvajal - Memorial Sloan-Kettering Cancer Center, New York, USA
New MEK inhibitor selumetinib is the first effective drug for advanced melanoma of the eye ( Dr Richard D. Carvajal - Memorial Sloan-Kettering Cancer Center, New York, USA )
1 Jun 2013
Next generation PI3 kinase inhibition
Dr Maurizio Scaltriti – Massachusetts General Hospital, Boston, MA, US
Next generation PI3 kinase inhibition ( Dr Maurizio Scaltriti – Massachusetts General Hospital, Boston, MA, US )
19 Apr 2013
Targeting tumour suppressor genes
Dr Douglas Lowy - National Cancer Institute, Bethesda, USA
Targeting tumour suppressor genes ( Dr Douglas Lowy - National Cancer Institute, Bethesda, USA )
19 Apr 2013
Robotic oesophagectomy
Dr Kemp Kernstine - University of Texas Southwestern Medical Center, United Stat...
Robotic oesophagectomy  ( Dr Kemp Kernstine - University of Texas Southwestern Medical Center, United States )
19 Dec 2012
Benefits of partaking in clinical trials
Lt. Col. David Hamilton - Lord Kitchener National Memorial Fund and NHS National...
Benefits of partaking in clinical trials ( Lt. Col. David Hamilton - Lord Kitchener National Memorial Fund and NHS National Cancer Peer Review, UK  )
15 Nov 2012
Analysing the efficacy of treatment through Response Evaluation Criteria in Soli...
Dr Yves Menu – Saint Antoine Hospital, Paris, France
Analysing the efficacy of treatment through Response Evaluation Criteria in Solid Tumors (RECIST) ( Dr Yves Menu – Saint Antoine Hospital, Paris, France )
9 Oct 2012
The first phase II trial for the management of oesophageal cancer
Prof David Ferry – New Cross Hospital, Wolverhampton, UK
The first phase II trial for the management of oesophageal cancer  ( Prof David Ferry – New Cross Hospital, Wolverhampton, UK )
8 Oct 2012
Gefitinib versus placebo in oesophageal cancer progressing after chemotherapy
Prof David Ferry - New Cross Hospital, Wolverhampton, UK
Gefitinib versus placebo in oesophageal cancer progressing after chemotherapy ( Prof David Ferry - New Cross Hospital, Wolverhampton, UK )
29 Sep 2012
Landscape of cancer care in Bangladesh
Dr Akram Hussain Syed – University Hospital Dhaka, Bangladesh
Landscape of cancer care in Bangladesh ( Dr Akram Hussain Syed – University Hospital Dhaka, Bangladesh )
20 Jul 2012